ESMO 23: Analysts Keep Faith In Revolution’s Multi-RAS Drug Despite Investor Fright

Revolution Medicines is aiming to go beyond Amgen and Mirati’s first-generation drugs with a multi-RAS targeting therapy - and despite a market sell-off after ESMO, analysts think the company think it is still on track.

Revolution Medicines

Revolution Medicines is one of the big share price losers following the European Society of Medical Oncology (ESMO) meeting, its stock declining more than 30% this week after the firm presented new data on the multi-RAS-targeting contender RMC-6236. 

That left the NASDAQ-listed biotech’s shares at just under $20 a share, but most sellside analysts think investor reaction is...

More from Clinical Trials

More from R&D